Capital Research & Management Co.. recently announced the acquisition of new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA). The institutional investor has increased its shareholding in the Healthcare company by 0.03% to 130.13 million shares with purchase of 37144.0 shares. This fresh investment now brings its stake to 11.88% valued currently at $1.5 billion. In addition, Capital Research & Management Co.. raised its holdings by 10.34 million to 43.43 million shares. And Capital Research & Management Co.. has lifted its position by 47.74% or 6.63 million shares – to 20.51 million shares.
With over 8.02 million Teva Pharmaceutical Industries Limited (TEVA) shares trading Monday and a closing price of $9.87 on the day, the dollar volume was approximately $79.13 million. The shares have shown a positive weekly performance of 2.49% and its price on 08/31/20 gained nearly 2.81%. Currently, there are 1.10B common shares owned by the public and among those 1.08B shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 23 analysts who have offered their price forecasts for TEVA have a consensus price objective of $12.26. The analysts have set the share’s price value over the next 12 months at a high of $17.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Teva Pharmaceutical Industries Limited stock is 2.80 for the next 12 months. The average price target is 19.03% above its last price level and an upside to the estimated low will see the stock lose -23.37% over that period. But an upside of 41.94% will see the stock hit the forecast high price target while mean target price for the stock is $12.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Teva Pharmaceutical Industries Limited are American Funds EuroPacific Growth, American Funds Growth Fund of Ame, and American Funds Investment Company. American Funds EuroPacific Growth owns 56.23 million shares of the company’s stock, all valued at over $648.88 million. American Funds Growth Fund of Ame bought 1.11 million shares to see its total holdings expand to 49.4 million shares valued at over $570.12 million and representing 4.51% of the shares outstanding. American Funds Investment Company now owns shares totaling to 2.08% of the shares outstanding.
Shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) opened at $9.65, up $0.05 from a prior closing price of $9.60. However, the script later closed the day at $9.87, up 2.81%. The company’s stock has a 5-day price change of 2.49% and -24.19% over the past three months. TEVA shares are trading 0.71% year to date (YTD), with the 12-month market performance up to 43.04% higher. It has a 12-month low price of $6.25 and touched a high of $13.76 over the same period. Currently, 8.02 million shares have been traded, compared to an average intraday trading volume of 9.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.84%, -14.73%, and -8.44% respectively.
Institutional ownership of Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares accounts for 53.20% of the company’s 1.10B shares outstanding. Mutual fund holders own 23.89%, while other institutional holders and individual stakeholders account for 29.18% and 0.14% respectively.
It has a market capitalization of $10.72B and a beta (3y monthly) value of 1.50. The stock’s trailing 12-month PE ratio is 3290.00, while the earnings-per-share (ttm) stands at $0.00. The company has a PEG of 1028.12 and a Quick Ratio of 0.70 with the debt-to-equity ratio at 1.90. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.26% over the week and 4.77% over the month.
Analysts forecast that Teva Pharmaceutical Industries Limited (TEVA) will achieve an EPS of $0.58 for the current quarter, $0.62 for the next quarter and $2.63 for 2021. The lowest estimate earnings-per-share for the quarter is $0.55 while analysts give the company a high EPS estimate of $0.61. Comparatively, EPS for the current quarter was $0.58 a year ago. Earnings per share for the fiscal year are expected to increase by 59.40%, and 5.02% over the next financial year. EPS should grow at an annualized rate of 3.20% over the next five years, compared to -17.70% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 23 brokerage firm advisors rate Teva Pharmaceutical Industries Limited (TEVA) as a “Moderate Buy” at a consensus score of 2.80. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 16 of the 23 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the TEVA, a number of firms have released research notes about the stock. Barclays stated their Equal Weight rating for the stock in a research note on August 06, 2020, with the firm’s price target at $10-$13. Goldman coverage for the Teva Pharmaceutical Industries Limited (TEVA) stock in a research note released on July 27, 2020 offered a Neutral rating with a price target of $12. SunTrust was of a view on June 01, 2020 that the stock is Buy, while Citigroup gave the stock Neutral rating on April 24, 2020, issuing a price target of $10. UBS on their part issued Buy rating on April 06, 2020.